Utama › Mielofibrosis › Illinois
Kajian klinikal Mielofibrosis di Illinois
7 kajian untuk Mielofibrosis sedang mencari peserta di lokasi di Illinois.
Bandar di Illinois
Teks kajian rasmi (Bahasa Inggeris)
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- University of Chicago, Chicago
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT04176198A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- University of Chicago Comprehensive Cancer Center, Chicago
- UC Comprehensive Cancer Center at Silver Cross, New Lenox
- University of Chicago Medicine-Orland Park, Orland Park
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT06661915A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
- University of Chicago Medical Center, Chicago
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT07008118Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Chicago, Chicago
Mengambil pesertaFasa 1
Umur 13 ke atas · Semua jantina · Dikemas kini 5 Mei 2026 · NCT04771572MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
- MPN Research Foundation, Chicago
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Jan 2026 · NCT07362225Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
- The University of Chicago, Chicago
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Dis 2025 · NCT03326310SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chicago
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.